Evaluation of cardiovascular risk in HIV patients: Clinical implication: Editorial

International Journal of Clinical Practice

Volumn 64, Issue 9, 2010, Pages 1173-1175

  Das, S ^a  

^a UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

BODY FAT DISTRIBUTION; CARDIOVASCULAR RISK; DYSLIPIDEMIA; EDITORIAL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARDIOVASCULAR DISEASES; HIV INFECTIONS; HUMANS; RISK ASSESSMENT; RISK FACTORS;

EID: 77954632715     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2010.02457.x     Document Type: Editorial

References (14)

1. Aboud MRK, Peters B. Cardiovascular risk evaluation and anti-retroviral therapy effects in an HIV cohort: implications for clinical management: CREATE 1 study. Int J Clin Pract 2010 64 : 1252 1259.
2. University of Nottingham Enug, QResearch Group. QResearch database. Available from: URL: http://www.qrisk.org/ (accessed 1 June 2010).
3. Neil HAPR, Armitage JM, Farmer AJ, Mant D, Durrington PN. Estimated 10-year cardiovascular risk in a British population: results of a national screening project. Int J Clin Pract 2008 62 : 1322 1331.
4. Friis-Moller N, Weber R, Reiss P et al. Cardiovascular disease risk factors in HIV patients - association with antiretroviral therapy. Results from the DAD study. AIDS 2003 17 : 1179 1193.
5. De Socio GVPG, Quirino T, Ricci E et al. Identifying HIV patients with an unfavorable cardiovascular risk profile in the clinical practice: results from the SIMONE study. J Infect 2008 57 : 33 40.
6. Hsue PWY, Schnell A, Ganz P et al. Association of abacavir and HIV disease factors with endothelial function in patients on long-term suppressive ART, 2009. 16th Conference on Retroviruses and Opportunistic Infections, Montreal; Abstract, 723
7. Meng QLJ, Lai H, Vlahov D et al. Coronary artery calcification, atherogenic lipid changes, and increased erythrocyte volume in black injection drug users infected with human immunodeficiency virus-1 treated with protease inhibitors. Am Heart J 2002 144 : 642 648.
8. Grunfeld CDJ, Wanke C, Currier JS et al. Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. AIDS 2009 23 : 1841 1849.
9. Satchell C, O'connor E, Peace A et al. Platelet hyper-reactivity in HIV-1-infected patients on abacavir-containing ART, 2009. 16th Conference on Retroviruses and Opportunistic Infections, Montreal; Abstract, 151LB
10. ASSIGN. Scottish Intercollegiate Guidelines Network. Risk estimation and the prevention of cardiovascular disease. A national clinical guideline Edinburgh: SIGN, 2007. http://www.sign.ac.uk/pdf/sign97.pdf (accessed 1 June 2010).
11. Hippisley-Cox JCC, Vinogradova Y, Robson J, May M, Brindle P. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ 2007 335 : 136.
12. Law MGF-MN, El-Sadr WM, Weber R et al. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D study. HIV Med 2006 7 : 218 230.
13. Copenhagen HIV programme. Cardiovascular disease: Framingham risk equation calculator http://www.cphiv.dk/TOOLS/Framingham/tabid/302/Default.aspx (accessed 1 June 2010).
14. Hurley LLW, Xu L, Silverberg M et al. Surveillance of cardiovascular and cerebrovascular event rates among HIV-infected and HIV-uninfected Californians: 1996-2008. 16th Conference on Retrovirus and Opportunistic Infection, Montreal 2009; Abstract: 710.